HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the ...

Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as "Ping An Bio") announced that it has entered into a non-binding memorandum (the "Investment ...

Scientists at Northwestern University have developed the fastest test yet for diagnosing hepatitis C virus (HCV). The highly accurate diagnostic delivers results to patients in just 15 minutes—up to ...

From high technology drone systems transforming live entertainment and AI software streamlining medical claims to renewable ...

Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors. Ping An ...

Sleep apnea is a disorder characterized by repeated obstructions or collapses of the upper airway during sleep. These ...

Future FinTech a leading comprehensive financial and digital technology service provider, announced today that on January 7, 2026, its wholly-owned subsidiary, Future FinTech (Hong Kong) Limited ...

The significant stock decline suggests investors may have concerns about the substantial investment and its long-term impact on Ping An’s financial position, despite the company’s assertion that the ...

Pennington Biomedical Research Center’s Associate Executive Director for Cores and Resources, Dr. Jennifer Rood, has agreed ...

Logan Jenner, a five-year-old battling acute myeloid leukemia, found new hope through a clinical trial that used Functional Precision Medicine to guide a personalized treatment approach after standard ...

Nanoparticle technology offers significant market opportunities in pharmaceuticals and biomedicine, enhancing drug delivery, solubility, and targeted therapy. This field supports advancements in ...

As of Wednesday, December 24, Impact BioMedical Inc.’s IBO share price has dipped by 5.93%, which has investors questioning if this is right time to buy.